Medical Science Liaison hiring no longer follows commercial headquarters or launch geography. Medical affairs teams now hire MSLs across Europe, LATAM, APAC, and the Gulf to support investigator relationships, scientific exchange, clinical trials, and regional therapeutic expertise. The Medical Affairs Professional Society (MAPS) has documented the continued expansion of global and therapeutically specialized MSL teams in its industry benchmarking research.
That shift creates a problem for sponsors hiring in countries where they do not have a legal entity. Hiring an MSL internationally involves three separate layers: local employment law, medical affairs compliance, and country-specific healthcare professional interaction rules. An Employer of Record (EOR) can handle the employment layer, including payroll, contracts, and local labor compliance. The sponsor still owns scientific exchange, pharmacovigilance workflows, transparency reporting, and promotional-risk controls.
This guide explains how to hire Medical Science Liaisons internationally through an EOR, where MSL talent is concentrated, what credentials are commonly required by country, and which compliance frameworks medical affairs teams need to account for before hiring. It also covers where EOR structures fit cleanly, where a local entity makes more sense, and why contractor models often create classification risk for field medical roles.
EOR vs. recruiter vs. local entity for MSL hiring
Medical affairs teams hiring internationally usually evaluate three models: using an Employer of Record, working with a recruiting firm, or opening a local entity. These options solve different problems.
Recruiters help source candidates. An EOR becomes the legal employer in-country and handles payroll, contracts, and labor compliance. A local entity gives the sponsor full operational control but adds setup cost and administrative overhead.
For first MSL hires in a new market, many sponsors use an EOR structure before committing to a permanent entity.
The 5-Step Process for Hiring an MSL Through an EOR
The mechanics of hiring a Medical Science Liaison through an Employer of Record are similar to other regulated medical roles, but the compliance overlay is heavier. The five steps below are what a sponsor's medical affairs team runs end-to-end when hiring an MSL in a country where it has no entity.
Step 1: Define the country, therapeutic area, and scope of role
What happens: Before any candidate is sourced, medical affairs leadership documents what the MSL will do, in which country, against which compliance code.
What to specify:
- Country — driven by KOL distribution, trial-site density, and regulator access for the target indication
- Therapeutic area and the named investigators or KOLs the MSL will engage
- Scope of role in writing, country-by-country
- What is in scope: unsolicited scientific exchange on approved indications, congress engagement, advisory board logistics, investigator-initiated study support
- What is out of scope: comparative claims, unsolicited off-label discussion, distribution of non-approved promotional materials
Step 2: Verify the candidate's scientific credential and local registration
What happens: Confirm the candidate's terminal degree and any local professional registration that lets them use a regulated title in-territory.
Credential expectations vary by country:
Step 3: Select an EOR with owned entities in the target country
What happens: Choose the provider that will become the legal employer of the MSL in-country.
What to look for:
- Owned entities, not aggregator coverage. Aggregator models put a second legal employer between the sponsor and the MSL, which complicates SOP enforcement and pharmacovigilance intake — the two places where speed matters most for medical affairs.
- Direct experience in the target country's regulated employment regime. German works councils, French CSE consultations, Japanese fixed-term contract rules.
- Capital efficiency. Pre-funded payroll models sit awkwardly against biotech runway. Invoice-in-arrears keeps working capital available.
- Documented transition path to a sponsor-owned entity if the country team grows past 10 to 20 MSLs.
Step 4: Draft a country-compliant contract that maps scientific exchange vs. promotion
What happens: The EOR drafts the local employment contract; the sponsor's medical affairs and legal teams write the role-scope and code-compliance language.
The contract has two layers:
Layer 1 — Local employment law (the EOR's job):
- Statutory clauses, notice periods, probation, statutory benefits
- Minimum wage and working-time compliance
- Country-specific obligations (German contracts in German, French CDI structure, Japanese fixed-term rules)
Layer 2 — Medical-affairs compliance (the sponsor's job):
- Scope-of-role language reflecting the country's HCP-interaction code
- Reference to sponsor SOPs the MSL must follow
- Adverse-event reporting obligations and pharmacovigilance intake path
- Transparency-reporting consent for transfers of value
- Off-label discussion prohibition and unsolicited-request handling
- IP assignment for any scientific work product
Country code reference:
Step 5: Run payroll through the EOR and keep medical-affairs compliance on the sponsor side
What happens: Once the contract is signed, operational responsibilities split cleanly between the EOR and the sponsor.
The EOR handles:
- Income tax withholding and statutory employer contributions
- Statutory benefits, leave accrual, and country-specific allowances
- Employment-law compliance (working hours, rest periods, termination procedure)
- Work permit sponsorship where applicable
- Maintenance of the local employment record
The sponsor handles (the EOR cannot absolve any of these):
- MSL-as-promotion classification under the country's HCP-interaction code
- Transparency reporting of transfers of value (Open Payments, transparence santé, JPMA Transparency Guideline, Italian Sunshine Act)
- Off-label communication risk in 1:1 KOL meetings
- Pharmacovigilance intake within EU GVP Module VI timelines or local equivalent
- Underlying professional registration if the MSL uses a regulated title
- Industry-association obligations under ABPI, EFPIA, JPMA, PhRMA membership
The defensible MSL EOR engagement therefore requires four sponsor-side workflows live before the start date:
- A country-specific SOP for scientific exchange vs. promotion
- A transparency-reporting workflow that captures MSL transfers of value from day one
- A pharmacovigilance intake path the MSL is trained on
- Clarity on whether the MSL's underlying credential is in scope and how it is maintained
Without those four, the cleanest EOR contract in the world will not protect the sponsor from a code-of-practice complaint.
The bottom line: Steps 1 through 4 prepare the hire. Step 5 is where most medical affairs teams underestimate what stays with the sponsor. The EOR is the legal employer; it is not the medical-affairs compliance function. Get that division of labor written down before the first MSL starts, and the rest of the program runs smoothly.
Why MSL hiring no longer lines up with commercial HQ geography
Three structural shifts pulled MSL hiring off the commercial-HQ map.
Trial geography moved. Industry-sponsored clinical trial activity has rebalanced away from a US/China duopoly. The FDA's 2024 Drug Trials Snapshots show pivotal trials enrolling participants across an increasingly long list of jurisdictions, and CRO disclosures back this up. Parexel highlights its India operations as a strategic hub, and IQVIA's annual report describes a global delivery footprint that is no longer concentrated in any single region. MSLs are field-based scientific peers to investigators; when investigators move, MSL coverage has to follow.
KOL networks are denser outside the US. For oncology, neurology, immunology, rare disease and cell-and-gene therapy, the publishing centers of gravity sit at academic medical centers in the EU, UK, Japan, Brazil and increasingly the Gulf. A single therapeutic-area MSL bench that is 80% US-based cannot service that KOL distribution.
The talent supply is genuinely international. PharmD, PhD and MD pipelines in Spain, Portugal, Poland, Germany, Italy, Brazil, Japan and South Korea routinely produce candidates with the scientific depth and English fluency MSL roles require. Pharma annual reports increasingly disclose medical-affairs hiring outside core HQ markets; see Roche's annual report and Novartis's annual report for examples of distributed medical-affairs structures.
The result: medical affairs hiring plans now routinely include three to seven countries the company has no entity in. That is the problem an EOR exists to solve, with caveats below.
Hiring Medical Science Liaisons by Country
Medical Science Liaison hiring requirements vary by country. The differences usually involve scientific credentials, healthcare professional interaction rules, transparency reporting obligations, and local employment considerations.
The table below summarizes how sponsors commonly approach international MSL hiring through an Employer of Record.
The common pattern across markets is that the EOR manages the employment relationship, while the sponsor remains responsible for scientific exchange controls, transparency reporting, pharmacovigilance processes, and medical affairs governance.
HCP-interaction rules to know before you hire MSLs through an EOR
This is where MSL hiring diverges from CRA or biostatistics hiring. Most countries do not regulate "MSL" as a profession. They regulate two adjacent things:
- The MSL's own underlying credential (pharmacist, physician), if they hold one and use a regulated title locally.
- The interaction between industry-employed scientific staff and healthcare professionals (HCPs).
The second category is where employers get caught. Practice licensure is a personal matter; an MSL who is a French pharmacist needs to keep their Ordre des Pharmaciens registration in good standing whether they are MSL-ing or not. HCP-interaction rules are the employer's problem.
Headline examples:
- Germany. The Arzneimittelgesetz (AMG) §§ 8 to 13 and the Heilmittelwerbegesetz (HWG) constrain how industry communicates about medicinal products, including in 1:1 scientific exchange. The line between scientific exchange and promotion is enforced strictly; misclassifying a launch-window MSL interaction as non-promotional carries real exposure under HWG advertising rules.
- France. The loi anti-cadeaux (Articles L.1453-3 et seq. of the Public Health Code) restricts industry benefits to HCPs, with Sunshine-style transparency reporting. MSL travel, advisory-board honoraria and meals all fall inside its perimeter.
- Italy. Industry-HCP transfers of value reporting is governed by Legge 62/2022 ("Sunshine Act"), with public registry obligations.
- United Kingdom. The ABPI Code of Practice governs scientific exchange, transparency and what constitutes promotion. MSL teams operate inside it whether the sponsor is a member of ABPI or not.
- EU-wide. The EFPIA HCP/HCO Code sets the minimum baseline above which national associations layer.
- United States. PhRMA Code on Interactions with Healthcare Professionals plus the federal Open Payments / Sunshine Act reporting regime.
- Japan. JPMA Code of Practice and JPMA Transparency Guideline set MSL-relevant standards; the PMDA regulates promotional materials.
- Global. The IFPMA Code of Practice is the umbrella ethical framework most multinational sponsors map their SOPs to.
Whether MSL activity counts as "promotion" under each of these codes is the unresolved question that drives most medical-affairs compliance work. The honest answer: it depends on the interaction, the document, and the regulator. EFPIA, ABPI and JPMA all distinguish legitimate scientific exchange from promotion, but the line is fact-specific. Sponsors that ignore the line discover it during audits.
EOR vs. local entity vs. contractor: which is right for your MSL hire
The structural choice is identical to other regulated medical hires (covered in the hub article), but the MSL-specific weighting differs.
Employer of Record fits when:
- The hire is a single-country MSL or a small (1 to 4 person) regional team.
- The MSL holds their own underlying credential and the employer is not relying on a clinical license to authorize the work.
- The sponsor needs the hire live inside weeks, not the three-to-nine-month entity-setup window.
- The sponsor wants to test whether a country justifies a permanent footprint before committing to entity overhead.
A local entity fits when:
- The MSL team in the country will exceed roughly 10 to 20 people.
- The sponsor also needs a local marketing-authorization holder, a local pharmacovigilance qualified person, or a local distributor relationship that an EOR cannot hold.
- The country has interaction-transparency reporting that the sponsor wants to file under its own legal name rather than via a third-party employer.
Contractor / 1099 almost never fits. MSL work is closely directed by the sponsor's medical affairs leadership, follows sponsor SOPs, uses sponsor-controlled scientific materials and is often integrated into the sponsor's CRM and HCP-interaction reporting. That is the textbook profile of misclassification under the US Department of Labor economic-realities test and analogous European tests. We cover the category broadly in the healthcare contractor-misclassification problem.
A practical decision shortcut: if you are about to hire your first MSL in a country where the sponsor has no entity, EOR is almost always the right starting move. Graduate to an entity if and when the team scales.
What an EOR does not handle when you hire MSLs
This is the honest-limits section. An EOR takes on the legal-employer role: contracts, payroll, statutory benefits, terminations, work permits. It does not absolve the sponsor of any of the following:
- MSL-as-promotion classification. Under German AMG and HWG, French Public Health Code, Italian Sunshine Act, ABPI Code and EFPIA Code, the question of whether a specific MSL interaction is scientific exchange or promotion is a sponsor-medical-affairs determination. The EOR is not a party to it.
- Transparency reporting obligations. Open Payments (US), French transparence santé, Italian Sunshine Act, JPMA Transparency Guideline reporting all sit with the sponsor, not the legal employer. An MSL employed via an EOR still triggers sponsor reporting obligations on transfers of value to HCPs in their territory.
- Off-label communication risk. Codes across all major jurisdictions prohibit unsolicited off-label promotion; what an MSL says in a 1:1 KOL meeting is the sponsor's risk regardless of who issues the paycheck.
- Local pharmacovigilance touchpoints. If an MSL hears of an adverse event from an HCP, the sponsor's PV system must capture it inside the regulator's reporting clock. EU GVP Module VI timelines do not pause because the employer is an EOR.
- Underlying professional registration. If the MSL is a registered pharmacist or physician using their title locally, the regulator that issued the license sets the rules. The EOR cannot vouch for or maintain that registration.
- Industry-association membership obligations. ABPI, EFPIA, JPMA and PhRMA membership commitments bind the sponsor, not the EOR.
A defensible MSL hire via EOR therefore requires: (1) a clear sponsor-side SOP for scientific exchange vs promotion in the target country, (2) a sponsor-side transparency-reporting workflow, (3) a sponsor-side PV intake path, and (4) clarity on whether the MSL's underlying credential is in scope. Without those, the cleanest EOR contract in the world will not save the sponsor from a code-of-practice complaint.
FAQs
How do medical affairs teams hire MSLs through an Employer of Record?
They contract with an EOR that holds a legal entity in the target country. The EOR drafts a country-compliant employment contract, runs payroll, withholds tax, and administers statutory benefits. The sponsor sets compensation, defines the scientific-exchange scope of the role, retains medical-affairs SOPs, and handles transparency reporting and pharmacovigilance intake. First MSL hires typically go live in 2–3 weeks vs. 3–9 months to open a local entity.
How long does it take to hire an MSL through an EOR?
2–3 weeks from signed offer to first payroll cycle in most countries. Credential verification, right-to-work checks, and benefits enrollment run in parallel. Visa-sponsored hires take longer; check the country-specific work-permit timeline on the buyer call.
Can an MSL be hired as a contractor instead of through an EOR?
Almost never. MSL work is closely directed by the sponsor's medical affairs leadership, follows sponsor SOPs, uses sponsor-controlled scientific materials, and is integrated into the sponsor's CRM and HCP-interaction reporting. That profile fails contractor classification under the US DOL economic-realities test, IR35 in the UK, the DBA Act in the Netherlands, Scheinselbstständigkeit in Germany, and equivalent tests across most major MSL hiring markets. EOR is the compliant path.
Do MSLs need a clinical license?
Usually no. MSL work itself is not a licensed clinical activity in most countries. Many MSLs hold a PharmD, PhD or MD, but they are doing scientific exchange, not treating patients. If the MSL is a registered pharmacist or physician using their title locally, the underlying registration must remain in good standing under the rules of the issuing regulator.
What is the difference between an EOR and an MSL recruiter?
An MSL recruiter helps identify and source candidates. An Employer of Record becomes the legal employer in the target country and handles payroll, local employment contracts, tax withholding, statutory benefits, and labor-law compliance. Sponsors often use both models together: a recruiter sources the MSL candidate, and the EOR employs them in-country where the sponsor does not yet have an entity.
Further reading
- Why Medical Companies are Turning to Employer of Record services
- How to Hire Clinical Research Associates Globally
- How Medical Device Companies are Staffing Rollouts
- EOR for Biotech Startups on Tight Runway
- Global Hiring for Digital-Health and Telemedicine Companies
- How Tech Companies Are Turning to Employer of Record Services
Where this leaves medical affairs leaders
MSL hiring is moving toward the countries where KOLs, trial sites, and scientific talent already sit. For many sponsors, that means hiring outside their commercial HQ country before they have a local entity.
An Employer of Record can help sponsors hire the first one to several MSLs in a new country through a compliant employment structure. The sponsor still owns medical-affairs compliance, transparency reporting, pharmacovigilance processes, and scientific-exchange controls.
For the broader operational model, see why medical companies use EOR. For country-specific onboarding, payroll, and employment guidance for field medical teams, speak with Borderless AI's healthcare team.
